Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials - PubMed (original) (raw)

Clinical Trial

. 2018 May;15(5):570-580.

doi: 10.1513/AnnalsATS.201704-326OC.

Nigel A Scott 1 2, Andrew Vernon 1, Naomi K Tepper 1, Stefan V Goldberg 1, Kevin Schwartzman 3, Chi-Chiu Leung 4, Neil W Schluger 5, Robert W Belknap 6, Richard E Chaisson 7, Masahiro Narita 8 9, Elizabeth S Machado 10, Marta Lopez 11, Jorge Sanchez 12 13, Margarita E Villarino 1, Timothy R Sterling 14

Affiliations

Clinical Trial

Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials

Ruth N Moro et al. Ann Am Thorac Soc. 2018 May.

Abstract

Rationale: Data are limited regarding the safety of 12-dose once-weekly isoniazid (H, 900 mg) plus rifapentine (P, 900 mg) (3HP) for latent infection treatment during pregnancy.

Objectives: To assess safety and pregnancy outcomes among pregnant women who were inadvertently exposed to study medications in two latent tuberculosis infection trials (PREVENT TB or iAdhere) evaluating 3HP and 9 months of daily isoniazid (H, 300 mg) (9H).

Methods: Data from reproductive-age (15-51 yr) women who received one or more study dose of 3HP or 9H in either trial were analyzed. Drug exposure during pregnancy occurred if the estimated date of conception was on or before the last dose date.

Results: Of 126 pregnancies (125 participants) that occurred during treatment or follow-up, 87 were exposed to study drugs. Among these, fetal loss was reported for 4/31 (13%) and 8/56 (14%), 3HP and 9H, respectively (difference, 13% - 14% = -1%; 95% confidence interval = -17% to +18%) and congenital anomalies in 0/20 and 2/41 (5%) live births, 3HP and 9H, respectively (difference, 0% - 5% = -5%; 95% confidence interval = -18% to +16%). All fetal losses occurred in pregnancies of less than 20 weeks. Of the total 126 pregnancies, fetal loss was reported in 8/54 (15%) and 9/72 (13%), 3HP and 9H, respectively; and congenital anomalies in 1/37 (3%) and 2/56 (4%) live births, 3HP and 9H, respectively. The overall proportion of fetal loss (17/126 [13%]) and anomalies (3/93 [3%]) were similar to those estimated for the United States, 17% and 3%, respectively.

Conclusions: Among reported pregnancies in these two latent tuberculosis infection trials, there was no unexpected fetal loss or congenital anomalies. These data offer some preliminary reassurance to clinicians and patients in circumstances when these drugs and regimens are the best option in pregnancy or in women of child-bearing potential. This work used the identifying trial registration numbers NCT00023452 and NCT01582711, corresponding to the primary clinical trials PREVENT TB and iAdhere (Tuberculosis Trials Consortium Study 26 and 33).

Keywords: latent tuberculosis infection treatment; pregnancy outcomes; safety assessment.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Pregnancy events safety assessment. This figure shows the total number of participants who were enrolled in the PREVENT TB and the iAdhere trials. Certain groups were excluded to select women of reproductive age who were evaluated in this analysis. In addition, pregnancies in which the estimated date of conception occurred after the last study dose were excluded to identify pregnancies that had been exposed to the study drugs. *Reasons for ineligibility: false positive TST (n = 3), lack of sensitivity test for the index case (n = 4), negative tuberculosis culture of the source (n = 31), isoniazid and rifapentine resistant of the source (n = 53), tuberculosis at enrollment (n = 1). †One participant reported 2 pregnancies (EDC occurred before and after the LD for each pregnancy). 3HP = 12-dose once-weekly regimen of isoniazid (900 mg) plus rifapentine (900 mg); 9H = 9-month daily isoniazid (300 mg); EDC = estimated date of conception; LD = last study dose; TST = Tuberculin Skin Test.

References

    1. Centers for Disease Control and Prevention . Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. Atlanta: U.S. Department of Health and Human Services; 2005_MMWR_ 2005;54(No. RR-12):1–69 -PubMed
    1. World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015 22.
    1. Crampin AC, Glynn JR, Floyd S, Malema SS, Mwinuka VK, Ngwira BM, et al. Tuberculosis and gender: exploring the patterns in a case control study in Malawi. Int J Tuberc Lung Dis. 2004;8:194–203. -PubMed
    1. Rhines AS. The role of sex differences in the prevalence and transmission of tuberculosis. Tuberculosis (Edinb) 2013;93:104–107. -PubMed
    1. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis. 1998;2:96–104. -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources